GFM
ABUS icon

GF Fund Management’s Arbutus Biopharma ABUS Stock Holding History

GF Fund Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.4K Buy
4,300
+522
+14% +$2.28K ﹤0.01% 503
2025
Q4 		$18.2K Sell
3,778
-346
-8% -$1.56K ﹤0.01% 516
2025
Q3 		$18.7K Sell
4,124
-728
-15% -$2.67K ﹤0.01% 496
2025
Q2 		$15K Hold
4,852
– – ﹤0.01% 526
2025
Q1 		$16.9K Buy
4,852
+873
+22% +$2.91K ﹤0.01% 519
2024
Q4 		$13K Buy
+3,979
New +$14.6K ﹤0.01% 514

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

GF Fund Management's ABUS Position: Q1 2026 in Review

GF Fund Management increased its Arbutus Biopharma (ABUS) stake by 14% in Q1 2026, buying an estimated $2.28K and bringing the position to 4,300 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #503.

GF Fund Management first reported a position in ABUS in Q4 2024 and has held it in 6 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • GF Fund Management held 4,300 shares of Arbutus Biopharma worth $19.4K as of Q1 2026.
  • GF Fund Management bought 522 Arbutus Biopharma shares in Q1 2026, an estimated $2.28K.
  • Arbutus Biopharma made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #503 holding.
  • GF Fund Management first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 6 quarters since.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.